Clonaid is an American-based human cloning organization, registered as a company in the Bahamas. Founded in 1997, it has philosophical ties with the UFO religion Raëlism, which sees cloning as the first step in achieving immortality. On December 27, 2002, Clonaid's chief executive, Brigitte Boisselier, claimed that a baby clone, named Eve, was born. Media coverage of the claim sparked serious criticism and ethical debate that lasted more than a year. Florida attorney Bernard Siegel tried to appoint a special guardian for Eve and threatened to sue Clonaid, because he was afraid that the child might be treated like a lab rat. Siegel, who heard the company's actual name was not Clonaid, decided that the Clonaid project was a sham. Bioethicist Clara Alto condemned Clonaid for premature human experimentation and noted the high incidence of malformations and thousands of fetal deaths in animal cloning.
Company founding
On May 31, 1997, an issue of the popular science magazine New Scientist said that the International Raëlian Movement was starting a company to fund the research and development of human cloning. This alarmed bioethicists who were opposed to such plans. They warned lawmakers against failing to regulate human cloning. At the time, European countries such as Britain had banned human cloning, but the United States had merely a moratorium on the use of federal funds for human cloning research. U.S. President Bill Clinton requested that private companies pass their own moratorium. Claude Vorilhon, the founder of Raëlism, was opposed to this move and denied that the technology used to clone was inherently dangerous.
On June 15, 1998, Brigitte Boisselier said the headquarters of Clonaid was located in Las Vegas and that Clonaid did not have enough funds for human cloning research. On December 19, 1998, a New Scientist article said the cost of Clonaid cloning services would be $200,000, much lower than the $2.3 million that researchers at Texas A&M University planned to use for cloning a dog named Missy. Mainstream scientists said it was unlikely that Clonaid would be able to clone anything in the near future. Although the project's ultimate objective was human cloning, Boisselier said that pet cloning would help finance the operations.
Premise
On June 9, 1997, Clonaid stated its intention to offer homosexual and/or infertile couples the chance to have a genetically identical child and take a step toward immortality. According to an Internet announcement, the Raëlian leader and a group of investors founded a company in the Bahamas and called it Valiant Venture Ltd., whose project mission was named Clonaid. Valiant Venture expected to have one million potential customers.
Claude Vorilhon held a meeting in a Montreal hotel on September 21, 2000, where he announced that a wealthy American couple was willing to fund the Clonaid project. The first pending clone, according to Vorilhon at the time, was the couple's 10-month-old girl, who had died due to a medical mistake. He said that the couple was willing to pay $1,500,000 to clone their deceased daughter, but the wife was not willing to be the surrogate mother. Jamie Grifo, a fertility specialist at the New York University School of Medicine, and Nobel laureate Paul Berg of Stanford University said that Vorilhons was providing a false hope that the child was going to be the same one. Boisselier revealed the roles of four scientists she says were involved—"a biochemist, a geneticist, a cell fusion expert and a French medical doctor"—but without revealing their identity. She did not identify the wealthy American couple.